Dhansa Labs Ltd (DHANSA) is currently trading at 24.20 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Dhansa Labs Limited (formerly Ambey Laboratories) is an ISO 9001:2015‑certified manufacturer and supplier of agrochemical technicals and formulations, producing 2,4‑D variants, Chlorpyriphos, Thiamethoxam, Pretilachlor and other crop protection chemistries from its Behror, Rajasthan facility and servicing domestic corporates and export markets including Australia, Latin America and the United States. Management reported FY26 consolidated revenue of Rs. 141.54 crore, EBITDA of Rs. 12.22 crore (8.55% margin) and PAT of Rs. 5.52 crore (3.87% margin), while announcing a brownfield Atrazine expansion and a large renewable energy pivot which together could materially change future revenue composition and scale. The company is diversifying into renewable energy through two subsidiaries: a 15 TPD Compressed Biogas (CBG) plant with Rs. 120 crore capex and a biomass pellets/biofuels plan, backed by an Rs. 85 crore bank sanction and warrant proceeds, plus a 350‑acre Napier grass program to secure long‑term feedstock and build carbon credit inventory. Key near‑term financial and operational risks surfaced during the call: trade receivables jumped materially (c. Rs. 13 crore), operating cash flows were weaker, and management expects normalization in H1 FY27; capacity utilization remained around 71% prompting the current capex to reach higher utilization and revenue targets. Dhansa Labs has signalled clear strategic priorities—brownfield capacity expansion for atrazine, export market focus, and vertical integration into renewables—funded via modest debt, accrued cash and equity/warrant proceeds, aiming for prudent capital allocation while pursuing diversification at scale.

Over the past 52 weeks, Dhansa Labs Ltd has traded between a low of ₹16.20 and a high of ₹47.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Dhansa Labs Ltd has a market capitalization of approximately 65.11. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Dhansa Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 11.52 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 65.11 Cr, Dhansa Labs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Dhansa Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Dhansa Labs Ltd is 11.52. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.